The Big Picture
Globally, GSK has an impressive community investment program. In 2011, GSK’s global community investment was valued at £204 million, £126 million of this comprises of product donations. We focus our efforts on lymphatic filariasis (LF), HIV/AIDS and malaria as well as diarrhoea-related disease in children. GSK Australia is a part of this global program.
Recognised as the leader in the Access to Medicines Index, an independent NGO/investor ranking of pharmaceutical companies.
1.1 bilion doses
Supplied 1.1 billion vaccine doses for prevention of serious diseases to nearly 80% of the developing world.
R&D investment into 12 diseases of particular importance for the developing world.
349 million anti-retroviral tablets supplied to the developing world at preferential prices, including 279 million supplied by generic manufacturers licensed by GSK. GSK has supported 65 projects in 63 countries around the world in partnership with 54 organisations over the last eight years, through the Positive Action program.
Expanding our donation of albendazol
Our albendazol program targets two neglected tropical diseases - lymphatic filarisis (LF) and soil transmitted helminths (STH). In 2011 we shipped 603 million tablets for these diseases. From 2012 we are commited to donating 1 billion albendazol treatments each year to target LF and STH infection.
PHASE, a low-cost education program helping to reduce diarrhoea-related disease by encouraging school children to wash their hands, has reached over 1.4 million children and their families globally. PHASE operates in 16 countries including Bangladesh, Kenya, Uganda, Zambia, Nicaragua, Peru, Mexico and Tajikistan.
GSK, with five other Australian pharmaceutical companies, is an active member of the Collaboration for Health in PNG with the Australian Society of HIV Medicine and National Association of People Living with HIV. The program works with the Catholic Health system to address the rising rates of HIV in PNG by increasing health care capacity through mentoring visits and training, as well helping reduce the stigma associated with HIV positive people.
Since 2001 we have committed more than £3 million through our African Malaria Partnership (AMP) to encourage behavioural change, such as sleeping under insecticide-treated bed nets and seeking treatment in the early stages of the disease.
We have also worked in partnership with the World Health Organisation, UK Government and academia on a new malaria treatment, Lapdap, developed specifically for the developing world. A malaria vaccine is in clinical trials.
Read more about our global community investment program